Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | PRNP | P04156 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30106721 | 1.00 | NCF1 (0.46) | NCF1CYP1A2NOS2BACE1CA12 | |
| Selenium SCHEMBL32667944 | 0.96 | NCF1 (0.43) | NCF1CYP1A2NOS2BACE1CA12 | |
| SCHEMBL21580901 | 0.83 | NCF1 (0.43) | NCF1CYP1A2NOS2BACE1CA12 | |
| SCHEMBL10020390 | 0.82 | ALDH1A1 (0.53) | NCF1CYP1A2NOS2BACE1CA12 | |
| SCHEMBL9009627 | 0.81 | NCF1 (0.50) | NCF1CYP1A2NOS2BACE1CA12 | |
| SCHEMBL2028207 | 0.79 | S1PR3 (0.47) | NCF1CYP1A2NOS2BACE1CA12 | |
| SCHEMBL1129147 | 0.77 | NCF1 (0.46) | NCF1CYP1A2NOS2BACE1CA12 | |
| SCHEMBL3294485 | 0.77 | NCF1 (0.46) | NCF1CYP1A2NOS2BACE1CA12 | |
| SCHEMBL827081 | 0.77 | CYP1A2 (0.52) | NCF1CYP1A2NOS2BACE1CA12 | |
| Bromide SCHEMBL29161153 | 0.76 | CYP1A2 (0.50) | NCF1CYP1A2NOS2BACE1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027104-A1 | NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2026-01-29 | — | — | US | disclosed |
| WO-2024006881-A1 | WEE1 DEGRADING COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-04 | — | — | WO | disclosed |
| CN-116472292-A | Modified proteins and protein degrading agents | 上海睿跃生物科技有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-116217478-A | Synthesis method of 6-amino-3-difluoromethyl quinoline | 苏州康润医药有限公司 | 2023-06-06 | — | — | CN | disclosed |
| EP-4157888-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | Cullgen (Shanghai), Inc. (CN) | 2023-04-05 | — | — | EP | disclosed |
| EP-4101843-A1 | METHOD FOR PRODUCING AROMATIC HETEROCYCLIC RING-SUBSTITUTED DIFLUOROACETIC ACID DERIVATIVE | AGC INC. (JP) | 2022-12-14 | — | — | EP | disclosed |
| EP-4101842-A1 | METHOD FOR PRODUCING DIFLUOROMETHYL-SUBSTITUTED AROMATIC HETEROCYCLIC COMPOUND | AGC INC. (JP) | 2022-12-14 | — | — | EP | disclosed |
| WO-2022042707-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI) , INC. (CN) | 2022-03-03 | — | — | WO | disclosed |
| WO-2021239117-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI) , INC. (CN) | 2021-12-02 | — | — | WO | disclosed |
| CN-112939729-A | Method for carrying out hydrogen-deuterium exchange reaction on difluoromethyl aromatic hydrocarbon under base catalysis | 中国人民大学 | 2021-06-11 | — | — | CN | disclosed |
| US-20090018012-A1 | Process for Producing Olefin Copolymerization Catalyst and Process for Producing Olefin Copolymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-01-15 | — | — | US | disclosed |
| CN-101195672-A | Method for producing olefin-copolymerization catalyst and method for producing olefin-copolymers | SUMITOMO CHEMICAL CO (JP) | 2008-06-11 | — | — | CN | disclosed |
| CN-1320122-A | Pyrazole derivatives and salts thereof | DAIICHI SEIYAKU CO (JP) | 2001-10-31 | — | — | CN | disclosed |
| CN-1043761-C | Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA INC (CA) | 1999-06-23 | — | — | CN | disclosed |
| EP-0565185-B1 | Quinoline derivatives as leukotriene antagonists | MERCK FROSST CANADA INC (CA) | 1998-07-08 | — | — | EP | disclosed |
| CN-1152915-A | Quinoline derivatives as leukotriene antagonists | LEO PHARM PROD LTD (DK) | 1997-06-25 | — | — | CN | disclosed |
| CN-1083052-A | Fluorine-containing hydroxyalkylquinolinacids acids as leukotriene antagonists | MERCK FROSST CANADA INC (CA) | 1994-03-02 | — | — | CN | disclosed |
| US-5270324-A | Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1993-12-14 | — | — | US | disclosed |
| WO-1993021159-A1 | QUINOLINE DERIVATIVES AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1993-10-28 | — | — | WO | disclosed |
| EP-0565185-A1 | Quinoline derivatives as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1993-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027104-A1 | NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES | CBR3, HAX1, CBR1 | NCF1 1316/4885CYP1A2 520/4885NOS2 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.